logging in or signing up Therapeutic Drug Monitoring sandeep_bmreddy Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 682 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: November 21, 2012 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Therapeutic Drug Monitoring: Therapeutic Drug Monitoring Sandeep.B , M.Pharm , II Semester, Department of Pharmacy PracticeContents:: Contents: Introduction Necessity of TDM Objectives Criteria for TDM Drugs requiring TDM Sampling Examples Factors influencing plasma drug concentration Analytical techniques used in TDM Clinical interpretation of results Role of Pharmacist in TDM Limitations ReferencesIntroduction:: Introduction: Therapeutic drug monitoring is defined as a “ a process of assessing concentration of the drug in biological fluids such that it is maintained within the therapeutic range. ” It aims at individualizing the dose for a patient to obtain maximum benefit. TDM closely observes the changes in the signs and symptoms of patient and the related laboratory data as well which affect the clinical outcome of the therapy. TDM establishes safety and effectiveness of therapy.: Time Plasma drug concentration MEC MSC Therapeutic Range Toxic Level Subtherapeutic Level Plasma drug Concentration Vs Time PlotNecessity for TDM:: Necessity for TDM: TDM is necessary for certain drugs having narrow therapeutic range or non-linear pharmacokinetics, where the dosage individualization becomes difficult. It is useful in assessing the variability between the individual patient’s response to drug therapy which arises due to differences between: Dose of the drug and its plasma concentration ( Pharmacokinetic variability ) Concentration of the drug at the receptor site and its response ( Pharmacodynamic variability )Objectives:: Objectives: Obtaining maximum beneficial outcome of drug therapy by approximate dosing of drugs. Attaining the required therapeutic concentration of the drug within least time and maintaining the concentration within the therapeutic range. Providing medical advantage by reducing the chances of drug toxicity. Providing economic convenience to the patients by shortening their hospital stay. Monitoring of factors like disease state, patient’s characteristics, drug interactions etc., in order to reduce patient variability. Dosage adjustment in patients with pre-existing hepatic or renal impairment and thus preventing drug accumulation in the body. TDM can provide an effective means of individualization of dosing of some drugs that have unpredictable dose-response relationship.Criteria for TDM:: Criteria for TDM: The criteria for obtaining a valid TDM which is clinically effective is: A well established correlation among concentration of drug in plasma and its therapeutic response and toxicity. Meagre correlation between concentration of drug in plasma and its dose. An acceptable evidence for performing TDM i.e., no response of the patient to the drug therapy, patient’s non-compliance, signs and symptoms of toxicity. Availability of specific and well established methodology. Collection of biological samples at regular intervals. There should be sufficient clinical data which permits rapid and accurate interpretation of clinical outcome.Drugs requiring TDM:: Drugs requiring TDM: The following features of the drugs necessitate their TDM: Narrow therapeutic range Significant pharmacokinetic variability (ADME) Drugs which show therapeutic as well as ADR based on their relative concentrations Availability of cost effective drug assay Drugs which follow saturation metabolism: Anticancer drugs- Paclitaxel , Cisplatin , Methotrexate Antiepileptics - Phenytoin , Fosphenytoin , Valproic acid, Carbamazepin Cardiotonics - Digoxin Immunosupressants - Cyclosporin , Tacrolimus Antibiotics - Ampicilline , Vancomycin Antiarrythmics - Amiadarone , LidocaineSampling:: Sampling: Proper selection of Sample time is of vital importance in obtaining an effective TDM. Generally biological samples (mostly venous blood) are collected after the drug reaches steady state concentration. For most of the drugs, Steady-state concentration is reached at least after 5 biological half lives. The point in dosing interval which is least inconsistent is known as pre-dose or trough concentration. The dosing interval and duration of dosing are the factors which influence variations in drug concentrations in plasma.PowerPoint Presentation: Drug Therapeutic range Half-life in Adults Average time taken to reach steady state concentration Digoxin 0.5-2 mcg/l 30-50 hrs 7-12 days Phenytoin 10-20 mg/l 10-30 hrs 8-21 days Carbamazepine 5-12 mg/l l0-30 hrs 3-5 days Lithium 0.5-1 mmol /l 14-30 hrs 5-8 days Amiodarone 1-2.5 mg/l 27-105 days 3-6 months Cyclosporin 100-200 mcg/l 19 hrs 3-4 days Theophylline 7-15 mg/l Smokers (7-11 hrs) Nonsmokers (3-5 hrs) 24-36 hrs Gentamycin <0.5 mg/l 2-5 hrs <24 hrs Vancomycin 5-15 mg/l 3-8 hrs 24-48 hrs Valproate 50-100 mg/l 6-20 hrs 3-5 daysFactors influencing plasma drug concentration:: Factors influencing plasma drug concentration: Patient characteristics Patient compliance Dosage regimen and Duration of therapy Time of sampling Alteration in Protein binding Alteration in elimination of drugs Pathological characteristics Drug interactions Smoking and alcohol consumption Sampling and Laboratory errorsAnalytical techniques used in TDM:: Analytical techniques used in TDM: The techniques chiefly employed for detection of drugs in a TDM laboratory are: HPLC GC/MS LC/MS RIA PETINIA EIA EMIT FPIA CEDIA Chemiluminiscence One-step Dry Chemistry TechniqueClinical interpretation of results: Clinical interpretation of results Clinical conditions requiring TDM for drugs used for prophylaxis Collection of biological sample Transfer to laboratory and estimation of drug concentration by suitable method Interpretation of TDM results with reference to clinical conditions Inadequate/Lack of Clinical response Satisfactory Clinical response Below TR Within TR Above TR Check the follow up of therapy Increase dose if required If required a small change in dose should be considered Change or re consider drug therapy Check the follow up of therapy Below TR Within TR Above TR Other possible reasons for signs of toxicity should be considered. Laboratory errors should be checked Other possible reasons for signs of toxicity should be considered. Lower dose can be given if result indicates the relief of disease Discontinue the therapy and restart with a low doseRole of Pharmacist in TDM:: Role of Pharmacist in TDM: A clinical pharmacist may assist other health care professionals by advising them about correct use if TDM- sampling time, sampling technique and interpretation of results. They also may be engaged in: Selecting initial drug dosage regimen-dose, dosing interval, route of administration, dosage form. Depending upon the TDM results and patient’s response, revision and adjustment of dosage regimen should be done. Assessing various other reasons for unexpected results like patient’s non-compliance, medication or laboratory errors, DDIs etc. Evaluating and adjusting dosage for patients on haemodialysis . Managing acute drug interactions.Limitations of TDM:: Limitations of TDM: Scientific accuracy of drug assays Laboratory variability in reporting Validity of suggested target ranges. Active metabolites which contribute to the therapeutic response cannot be measured.References: References Birkett DJ. Therapeutic drug monitoring. Aust Prescr 1997;20:9-11 Therapeutic Drug Monitoring (TDM), An Educational Guide. www.siemens.com/diagnostics Summers, K. K., T. C. Hardin, S. J. Gore, and J. R. Graybill . 1997. Therapeutic drug monitoring of systemic antifungal therapy. J. Antimicrob . Chemother . 40:753-764. Schumacher GE. Clinical pharmacokinetics and therapeutic drug monitoring. Comprehensive pharmacy review; 7:732-741 Flexner D. Update on HIV pharmacology and therapeutic drug monitoring. Perspectives - Pharmacology and therapeutic drug monitoring Vol 9 Issue 3 July 2001THANK YOU…: THANK YOU… You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.